396: A new trick for old science, and biotech VCs' scrambled playbook
About this episode
Elaine and Allison discuss the latest biotech news, including the resurgence of old exon science and the challenges facing biotech VCs.
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.
People in this episode
Hosts: Elaine, Allison
Guest: Jason Mast
Topics covered
- biotech
- venture capital
- clinical testing
- FDA
- M&A
- Duchenne muscular dystrophy
Keywords
- biotech
- venture capital
- FDA
- clinical testing
- Duchenne muscular dystrophy
- M&A
- China
- artificial intelligence
Mentioned in this episode
Organizations: PhRMA, Food and Drug Administration, STAT, China, biotech VC firms, Duchenne muscular dystrophy
More episodes of The Readout Loud
- 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
- 395: Biotech investors' plea to Trump, and a busy M&A week
- 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
- 393: A conversation with the 'godfather' of biotech
- 392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.